title: [Role of inflammation on renal anaemia].
abstract: It is well-known the central role of inflammation in the inhibition of erythropoiesis and iron availability in chronic kidney disease (CKD) patients with erythropoietin (EPO)-resistant anaemia. This inflammatory action is mediated by suppressive cytokines (i.e. IL-6, TNF-, INF-) inhibiting differentiation and proliferation activities of erythroid cells in the EPO-indipendent phase of erythropoiesis and stimulating hepcidin production for iron retention in reticulo-endothelial system and enterocytes. EPO resistance is associated with adverse outcomes, such as cardiovascular disease, faster progression to end stage renal disease and mortality. Treatment of the causes of EPO hyporesponsiveness including chronic inflammation results in an improvement of anaemia and a reduction in EPO requirements.
authors.forename: Andrea
authors.initials: A
authors.lastname: Icardi
authors.forename: Paolo
authors.initials: P
authors.lastname: Sacco
authors.forename: Alice
authors.initials: A
authors.lastname: Tarroni
authors.forename: Laura
authors.initials: L
authors.lastname: Cappelletti
authors.forename: Mario
authors.initials: M
authors.lastname: Cozzolino
mesh_terms: D000740:Anemia / Q000188:drug therapy / Q000209:etiology*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018925:Chemokines / Q000037:antagonists & inhibitors; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000188:drug therapy; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D014807:Vitamin D / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D018925:Chemokines; D014815:Vitamins; D014807:Vitamin D